Current Report Filing (8-k)

Date : 12/23/2019 @ 9:05PM
Source : Edgar (US Regulatory)
Stock : Conatus Pharmaceuticals Inc (CNAT)
Quote : 0.31  0.0 (0.00%) @ 5:00AM
Conatus Pharmaceuticals share price Chart
After Hours
Last Trade
Last $ 0.33 ▲ 0.02 (5.48%)

Current Report Filing (8-k)










Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): December 18, 2019




(Exact Name of Registrant as Specified in its Charter)




Delaware   001-36003   20-3183915

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)


16745 West Bernardo Drive, Suite 250

San Diego, California

(Address of Principal Executive Offices)   (Zip Code)


Registrant’s telephone number, including area code: (858) 376-2600


(Former Name or Former Address, if Changed Since Last Report.)

16745 West Bernardo Drive, Suite 200, San Diego, California 92127



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


Securities registered pursuant to Section 12(b) of the Act:

Title of each class:  


Trading symbol:

  Name of each exchange on which registered:
Common Stock, par value $0.0001 per share   CNAT   The Nasdaq Capital Market



Item 1.01  Entry into a Material Definitive Agreement


On December 18, 2019, Conatus Pharmaceuticals Inc. (the “Company”) and Pacific Real Estate Partnership (“Subtenant”) entered into a Sublease Agreement (the “Sublease”), pursuant to which the Company agreed to sublet to Subtenant approximately 13,225 rentable square feet of office space (the “Premises”), which the Company currently leases, at 16745 West Bernardo Drive, San Diego, CA 92127. The Sublease is subordinate to the Office Lease Agreement between the Company and The Point Office Partners, LLC (the “Landlord”).


The term of the Sublease will commence five days after approval from the Landlord and will expire on September 30, 2020. At the commencement of the Sublease, the Company will sublet 9,954 rentable square feet of the Premises (the “Initial Premises”), and the Company will sublet the remaining 3,271 rentable square feet of the Premises (the “Expansion Premises”) commencing on April 1, 2020. Subtenant will pay the Company monthly rent in the amount of $22,396.50 for the Initial Premises and $3,271.00 for the Expansion Premises. In addition, Subtenant will pay 100% of electricity used in the subleased Premises and any other utilities and services exclusively for the subleased Premises. The Company will also receive a security deposit of $25,667.50


The Sublease contains customary provisions allowing the Company to, among other things, terminate the Sublease in its entirety and retake the Premises if Subtenant fails to remedy certain defaults of its obligations under the Sublease within specified time periods.


The description of the terms and conditions of the Sublease set forth herein is not complete and is qualified in its entirety by reference to the full text of the Sublease, a copy of which will be filed as an exhibit to the Company’s annual report on Form 10-K for the year ending December 31, 2019.








Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: December 23, 2019 By:   /s/ Keith W. Marshall, Ph.D.
  Name:   Keith W. Marshall, Ph.D.
  Title:   Executive Vice President, Chief Operating Officer and Chief Financial Officer


Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart

1 Year : From Apr 2019 to Apr 2020

Click Here for more Conatus Pharmaceuticals Charts.

Conatus Pharmaceuticals (NASDAQ:CNAT)
Intraday Stock Chart

Today : Monday 6 April 2020

Click Here for more Conatus Pharmaceuticals Charts.

Latest CNAT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200406 06:59:41